Photobiomodulation — the clinical term for red light therapy — has been studied since the 1960s. The mechanism is well documented: specific wavelengths of red and near-infrared light are absorbed by cytochrome c oxidase, an enzyme in the mitochondrial electron transport chain. The result is increased ATP production, reduced oxidative stress, and accelerated cellular repair.
What wavelengths matter
Not all red light is the same. The two wavelengths with the strongest research backing are 630–660nm (red, absorbed at the skin surface) and 810–850nm (near-infrared, penetrates deeper tissue and skull). Devices that do not specify wavelength are not worth evaluating further.
What the research actually covers
The strongest evidence base is in hair follicle stimulation — multiple randomised controlled trials exist, and several devices hold FDA clearance specifically for androgenic alopecia. Wound healing, muscle recovery, and joint inflammation have meaningful research support. Cognitive and neurological applications are earlier-stage but actively studied at credible institutions.
What to watch out for
The consumer market is full of underpowered devices that do not deliver sufficient irradiance at scalp or skin distance. Power density matters — target 5–10 mW/cm² at the surface you are treating. Session duration matters — most protocols use 10–20 minutes daily. Consistency matters — single sessions produce little measurable effect.
